

Special Issue

Molecular Approaches in Early Detection and Targeted Therapies for Pancreatic Cancer

Message from the Guest Editor

Dear colleagues,

Pancreatic cancer remains one of the most lethal malignancies, with an overall five-year survival rate of approximately 11% and projected to become the second leading cause of cancer death by 2030. Late diagnosis, with only 10–15% of patients presenting with resectable disease, emphasizes the urgent need for innovative molecular detection strategies across all pancreatic cancer subtypes.

Molecular approaches have shown great promise in addressing these challenges. Recent advances in multi-omics technologies, understanding of tumor–stroma interactions, and tumor immune microenvironment are enabling the discovery of novel biomarkers for early diagnosis, elucidating key oncogenic pathways, and facilitating the development of targeted therapies that disrupt specific oncogenic pathways and tumor microenvironment components.

This Special Issue welcomes papers focusing on molecular strategies for the early detection and personalized treatment of pancreatic cancer. We seek contributions that advance our understanding of pancreatic cancer molecular pathogenesis and accelerate the development of clinically meaningful diagnostic and therapeutic innovations.

Guest Editor

Dr. Hassan Mubarak Ishqi

Department of Surgery, School of Medicine, Washington University in Saint Louis, Saint Louis, MO, USA

Deadline for manuscript submissions

25 January 2026



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/246059

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago,
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,
New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC,
PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and
other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 17.8 days after
submission; acceptance to publication is undertaken in 2.7
days (median values for papers published in this journal in
the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and
reviewer names are published annually in the journal.